Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA

Journal of Immunology

Volumn 165, Issue 10, 2000, Pages 5713-5719

  Koido, S ^a   Kashiwaba, M ^a   Chen, D ^a   Gendler, S ^a   Kufe, D ^a   Gong, J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; MUC 1 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; FEMALE; GENETIC TRANSCRIPTION; IMMUNOCHEMISTRY; INGUINAL LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0034670002     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.10.5713     Document Type: Article

References (57)

1. The dendritic cell system and its role in immunogenicity
2. The hematopoietic development of dendritic cells: A distinct pathway for myeloid differentiation
3. + T lymphocytes by human blood dendritic cells in vitro
4. The tissue distribution of the B7-2 costimulator in mice: Abundant expression on dendritic cells in situ and during maturation in vitro
5. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells
6. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
7. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
8. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
9. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
10. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
11. + T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia
12. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens
13. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
14. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
15. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA
16. Cancer therapy using a self-replicating RNA vaccine
17. Immunotherapy of cancer with dendritic-cell-based vaccines
18. Transfected human dendritic cells as cancer vaccines
19. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors
20. The role of tumor-associated antigens in the biology and immunotherapy of breast cancer
21. Mimic 1 of MUC1
22. The epithelial mucin, MUC1, of milk, mammary gland and other tissues
23. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines
24. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells
25. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA
26. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells
27. Carbohydrate epitopes and mucins expressed by 17 human ovarian carcinoma cell lines
28. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides
29. Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls
30. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model
31. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells
32. Isolation and characterization of the human chromosomal gene for polypeptide chain elongation factor-2α
33. pEF-BOS, a powerful mammalian expression vector
34. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7
35. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen
36. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
37. + lymphcytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice
38. Development of a novel bi-specific monoclonal antibody approach for tumour targeting
39. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21
40. MUC1 and cancer
41. Induction of antigen-specific antitumor immunity with adenoviral-transduced dendritic cells
42. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells
43. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
44. T cell suppression as a mechanism for tolerance to MUC1 antigen in MUC1 transgenic mice
45. Dendritic cells and the control of immunity
46. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma
47. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage
48. Strain-specific variations in the development of dendritic cells in murine bone-marrow cultures
49. 11-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-plused dendritic cells
50. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12
51. IL-12: A key cytokine in immune regulation
52. Induction of Th1 cell-mediated protective immunity to Schistosoma mansoni by co-administration of larval antigens and IL-12 as an adjuvant
53. B7-1 and interleukin 12 synergistically induce effective antitumor immunity
54. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state
55. + T cells
56. + T cells in vivo
57. Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1